Inventor · disambiguated record
Katherine Galvin
Also filed as: GALVIN KATHERINE · GALVIN KATHERINE A · GALVIN KATHERINE M
4 granted patents·25 pending applications·6 citations·filing 1999–2020
65Inventor score
Top patents by PatentIndex Score
29 records- 0166US7696316B221910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2006·Granted Apr 13, 2010·1 cites·14 claims
- 0266US2009226451A1Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 0361US2009226448A1Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 0461US2009226449A1Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921, and 33751 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2009·Application pending·0 cites
- 0558US10426782B2Pharmaceutical formulations of a pan-RAF kinase inhibitor and processes for their preparationMILLENNIUM PHARM INC·Filed 2015·Granted Oct 1, 2019·1 cites·6 claims
- 0655US2011165147A1Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2011·Application pending·0 cites
- 0753US2003082738A11983, 52881, 2398, 45449, 50289, and 52872, novel G protein-coupled receptors and uses thereforMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 0852US2003215860A1Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 0951US2003097668A1Compositions and methods for the treatment and diagnosis of cardiovascular diseaseMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 1050US2003219806A1Novel 18607, 15603, 69318, 12303, 48000, 52920, 5433, 38554, 57301, 58324, 55063, 52991, 59914, 59921 and 33751 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 1150US2005037946A1Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061, 17662, 1468, 12282, 6350, 9035, 1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123, 12788, 17729, 65552, 1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 41922, 2552, 2417, 19319, 43969, 8921, 8993, 955, 32345, 966, 1920, 17318, 1510, 14180, 26005, 554, 16408, 42028, 112091, 13886, 13942, 1673, 54946 or 2419MILLENNIUM PHARM INC·Filed 2004·Application pending·0 cites
- 1249US2004091929A1Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941MILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 1348US2004058355A1Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 1447US2002061522A11983, 52881, 2398, 45449, 50289, and 52872 novel G protein-coupled receptors and uses thereforFiled 2001·Application pending·0 cites
- 1546US2007015201A1Novel 18636, 2466, 43238, 1983, 52881, 2398, 45449, 50289, 52872 and 26908 molecules and uses thereforMILLENNIUM PHARM INC·Filed 2006·Application pending·0 cites
- 1645US2003138890A1Novel G protein-coupled receptor family members, human thioredoxin family members, human leucine-rich repeat family members, and human ringfinger family memberFiled 2002·Application pending·0 cites
- 1744US6359194B1Compositions and methods for the treatment and diagnosis of cardiovascular diseaseMILLENNIUM PHARM INC·Filed 1999·Granted Mar 19, 2002·4 cites·11 claims
- 1844US2020316067A1Combination of raf inhibitors and taxanesDOT THERAPEUTICS 1 INC·Filed 2020·Application pending·0 cites
- 1944US2003109044A1Methods of using 279, a human G protein-coupled protein receptorMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 2044US2003186273A115603, a human ion channel family member and uses thereforMILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 2142US2006275866A1Novel nucleic acid sequences encoding G-protein coupled receptorsMILLENNIUM PHARM INC·Filed 2005·Application pending·0 cites
- 2242US2019117652A1Combination of raf inhibitors and taxanesMILLENNIUM PHARM INC·Filed 2015·Application pending·0 cites
- 2342US2002077312A13700, a novel human protein kinase and uses thereforMILLENNIUM PHARM INC·Filed 2001·Application pending·0 cites
- 2441US2001044130A139406 protein, a novel seven transmembrane proteinMILLENNIUM PHARM INC·Filed 2001·Application pending·0 cites
- 2539US6939698B233945, a human glycosyltransferase family member and uses thereforMILLENNIUM PHARM INC·Filed 2002·Granted Sep 6, 2005·0 cites·19 claims
- 2638US2003215840A1Methods and compositions for treating cardiovascular disease using 1682, 6169, 6193, 7771, 14395, 29002, 33216, 43726, 69292, 26156, 32427, 2402, 7747, 1720, 9151, 60491, 1371, 7077, 33207, 1419, 18036, 16105, 38650, 14245, 58848, 1870, 25856, 32394, 3484, 345, 9252, 9135, 10532, 18610, 8165, 2448, 2445, 64624, 84237, 8912, 2868, 283, 2554, 9464, 17799, 26686, 43848, 32135, 12208, 2914, 51130, 19489, 21833, 2917, 59590, 15992, 2094, 2252, 3474, 9792, 15400, 1452 or 6585 moleculesMILLENNIUM PHARM INC·Filed 2003·Application pending·0 cites
- 2737US2003119742A1Methods and compositions to treat cardiovascular disease using 139, 258, 1261, 1486, 2398, 2414, 7660, 8587,10183, 10550, 12680, 17921, 32248, 60489 or 93804MILLENNIUM PHARM INC·Filed 2002·Application pending·0 cites
- 2835US2002006618A1Methods for using 20893, a human protein kinaseFiled 2001·Application pending·0 cites
- 2930US2018263979A1Combination of raf inhibitors and aurora kinase inhibitorsMILLENNIUM PHARM INC·Filed 2015·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →